Key result
Extended hinge length of human IgG3-like antibody enhanced early antiviral activity of VRC01 in SHIV-infected rhesus macaques.
Extending the hinge length of simian VRC01.2.LS antibodies enhances early antiviral activity and reduces plasma viral load in SHIV-infected rhesus macaques.
Answers are grounded in this paper and cite their sources.
Preclinical hinge extension improves bnAb activity in SHIV models; leaves open translation to human HIV immunotherapy.
FIG 1 Antiviral activity of VRC01 with modified hinge length.(A and B) In vitro antibody functions.(A) Neutralization potency of simian VRC01.2.LS antibodies with 1X (blue) or 3X (green) hinge compositions.Antibody concentrations at which 50% infectivity (IC 50 ) was observed are presented across a panel of SHIV virus sequences and production host cells.(B) Percent capture of infectious SHIV CH505 virus by simian VRC01.2.LS antibodies with varied hinge compositions and isotype control.(C) Phagocytic activity of simian VRC01.2.LS antibodies with different hinge compositions and an isotype control (gray) in THP-1 monocytes (left) and neutrophil-like DMSO-matured HL-60 cells.Symbol denotes mean, and error bars depict standard error of the mean across triplicate measures.(D) Study design of extended hinge broadly neutralizing antibody (simian VRC01.2.LS) impact on plasma viremia over time in SHIV.CH505-infected RMs.(E) Viral loads over the entire observation period in the seven animals treated with variant VRC01.2.LS as compared to four untreated controls (black).(F) Relative change in daily plasma viral load over the first 7 days after mAb infusion.(G) Change in plasma viral load 1 day after treatment (significance by two-tailed Mann-Whitney U test).(H) Plasma viral load from time of infusion to 1 and 2 weeks post-treatment (significance by Friedman ANOVA with Dunn's multiple hypothesis correction).(I) Linear regressiondefined slope of fold change in plasma viral load from day 1 to day 4 post-infusion (significance by two-tailed (Continued on next page)
No takes yet. Share an insight, caveat, or question.
Jones et al. (2026) studied SHIV infection (n=11). Variant VRC01.2.LS (extended hinge broadly neutralizing antibody) vs. Untreated controls was evaluated on Plasma viral load. Extended hinge length of human IgG3-like antibody enhanced early antiviral activity of VRC01 in SHIV-infected rhesus macaques.
Synapse has enriched 10 related papers. Consider them for comparative context: